Title:Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as
the Future of Systemic Lupus Erythematosus Treatment
Volume: 19
Issue: 3
Author(s): Gede Kambayana and Sandra Surya Rini*
Affiliation:
- Department of Internal Medicine, North Lombok Regional Hospital, West Nusa Tenggara, Indonesia
Keywords:
CAR T-cell therapy, CD19, B-cell, systemic lupus erythematosus, potential, targeted.
Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune illness with an unclear etiology
and a range of clinical manifestations. The therapeutic results of current conventional treatments
are frequently unsatisfactory. Many B-cell-directed immunotherapies have recently been discovered,
as B cells play a key role in the pathogenesis of SLE. However, large-scale rituximab trials
found that the antibody against CD20 was no better than a placebo. Autologous CAR T-cell therapy
has garnered considerable interest and is considered a potential treatment option for SLE.
CD19+CD20- B cells are thought to play an essential role in the onset and progression of SLE.
CD19-targeted CAR T-cells destroy B cells without requiring an accessory cell type, thereby decreasing
B cells more efficiently. Preclinical trials of CAR T-cells in mice have shown promising
results against SLE. The review aimed to shed light on autologous CD19-targeted CAR T-cells as a
potential treatment for SLE.
